{"id":"docetaxel-nedaplatin-fluorouracil","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation. Nedaplatin forms DNA crosslinks, preventing replication and transcription. Fluorouracil inhibits thymidylate synthase and is incorporated into RNA/DNA, disrupting nucleotide synthesis. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination regimen uses a microtubule-stabilizing taxane, a platinum-based DNA crosslinker, and an antimetabolite to inhibit cancer cell division and induce apoptosis through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:44.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (phase 3 investigation)"},{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT06102395","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2023-05-01","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab","enrollment":272},{"nctId":"NCT04437329","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":352},{"nctId":"NCT04834206","phase":"PHASE2","title":"Nedaplatin in Treatment for Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2021-05-01","conditions":"Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT04764149","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":801},{"nctId":"NCT04472403","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-26","conditions":"Nasopharyngeal Carcinoma, Metastasis, Chemotherapy","enrollment":2000},{"nctId":"NCT02721576","phase":"PHASE4","title":"A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-07-05","conditions":"Esophageal Neoplasms","enrollment":8},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT02721550","phase":"PHASE4","title":"A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-08-01","conditions":"Esophageal Neoplasms","enrollment":2},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03503136","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06","conditions":"Nasopharyngeal Carcinoma","enrollment":632}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DNF"],"phase":"phase_3","status":"active","brandName":"Docetaxel, nedaplatin, fluorouracil","genericName":"Docetaxel, nedaplatin, fluorouracil","companyName":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","companyId":"affiliated-cancer-hospital-institute-of-guangzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses a microtubule-stabilizing taxane, a platinum-based DNA crosslinker, and an antimetabolite to inhibit cancer cell division and induce apoptosis through multiple mechanisms. Used for Gastric cancer (phase 3 investigation), Advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}